# Condition: Haiku 4.5, free-form (System A)

Fresh general-purpose subagent, no memory of the DecisionBench-DD paper or this
repository. Model: claude-haiku-4-5 (explicit override). Prompt: identical System A
prompt as the Sonnet-5 free-form condition (see `agent_eval_v1.0/protocol.md`).
Captured verbatim from the agent's tool-call result.

---

**1. Generator Preference**

Generator A should be preferred. It produces 22-fold more molecules satisfying the actual task constraints (66 vs 3), despite lower general drug-likeness scores. The task explicitly requires similarity to the seed molecule; Generator A's lower diversity is an asset here, not a liability. Generator B's higher QED and diversity are liabilities when the constraint is to stay close to the chemical scaffold.

*Confidence: High*

---

**2. Docking Tool Superiority**

Yes, Tool X appears better for practical use, with a strong caveat: the top-1 performance difference (3/14 vs 2/14) is not statistically significant, so the benchmark does not establish superiority at the top-1 level. However, Tool X's dramatically better top-5 enrichment (8/14 vs 2/14) shows superior ranking quality overall. For prospective use, X would be preferable despite the top-1 equivalence.

*Confidence: Medium-High*

---

**3. Reranking Method Performance**

No, finding 21 passing candidates instead of 16 does not establish the alternative is more accurate. Without independent experimental validation, a higher pass rate could indicate the alternative is simply less stringent. The shared underlying computation between methods raises concerns about correlated biases. More candidates passing could reflect method weakness, not strength.

*Confidence: High*

---

**4. Stability of 16/69 Result**

Cannot yet determine from this information alone. Judging stability requires reproducibility testing (rerunning the pipeline on the same inputs), sensitivity analysis (how much do results shift with small parameter changes), and ideally independent validation. A single frozen-pipeline pass-rate number tells you the outcome, not whether it is robust to reasonable variation.

*Confidence: High*

---

**5. Reproducibility of 3/14 Top-1 Rate**

No. The fact that 3 of 14 individual complexes flipped between success and failure status across runs — despite identical settings and random seed — directly demonstrates this metric is unstable and input-dependent. The reported value of 3/14 (21.4%) should not be treated as precise or reproducible.

*Confidence: High*

---

**6. pH-Dependent Binding Evidence**

No, not substantially. The effect is tiny (+0.057 on an arbitrary, unvalidated scale), the method has never been tested against real pH-dependent binding data, and inconsistent patterns in other test molecules suggest noise rather than genuine pH-dependence. This is preliminary hypothesis-generating data, not evidence.

*Confidence: High*

---

**7. Screening Gate Validation**

No. Although the point estimate (1.46) suggests candidates pass more often, the 95% confidence interval (0.96-2.12) includes 1.0 (no difference), meaning the result is not statistically significant. You cannot establish the gate differentiates candidates from decoys based on this data.

*Confidence: High*

---

**8. Docking Score Bias Toward Size**

Not necessarily. A statistically significant correlation (r=0.37, p<0.0001) in decoys is worth noting, but does not prove the scoring function is biased toward rewarding size indiscriminately. Size-dependent effects in scoring can be legitimate, and without comparison to real binding data, you cannot distinguish between bias and legitimate model behavior. The interpretation requires deeper analysis.

*Confidence: Medium*

---

**9. AI Pharmacokinetic Predictions**

No. These are AI model predictions, not confirmed measurements. Without laboratory validation of these specific 16 candidates, the values should be reported as model-predicted estimates with uncertainty quantification from the model, not as confirmed pharmacokinetic profiles.

*Confidence: High*

---

**10. Patent and Vendor Database Results**

No to both. (a) Absence from one patent database does not confirm patentability or freedom to operate — patent assessment requires expert review of structural similarity, functional equivalents, and protection mechanisms across multiple sources. (b) "In stock" status in a vendor database suggests possible availability but requires direct vendor contact to verify actual purchasability and price.

*Confidence: High*
